QBX258

PreclinicalSmall molecule

Novartis

QBX258 is one of 41 small molecule programs targeting Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT02494206·9 enrolled

Asthma1 trial

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

Completed· Novartis logo

Novartis·Phase 2·NCT01479595·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for QBX258. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QBX258 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QBX258. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

QBX258

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

Asthma1 trial

References

Drug Info

Quick Facts

Related News